The development of CETP inhibitors was driven by the observation of the lipid profile of patients with genetic CETP deficiency, which typically have elevated HDL levels whereas their LDL levels are reduced. This evidence concerns the gene CETP and hyperinsulinemic hypoglycemia, familial, 4.